X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Merck Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs MERCK LTD - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA MERCK LTD TORRENT PHARMA/
MERCK LTD
 
P/E (TTM) x 28.5 33.3 85.6% View Chart
P/BV x 5.4 3.7 145.4% View Chart
Dividend Yield % 1.0 0.8 132.4%  

Financials

 TORRENT PHARMA   MERCK LTD
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
MERCK LTD
Dec-16
TORRENT PHARMA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs1,7681,060 166.8%   
Low Rs1,186623 190.3%   
Sales per share (Unadj.) Rs346.1632.4 54.7%  
Earnings per share (Unadj.) Rs55.245.7 120.7%  
Cash flow per share (Unadj.) Rs73.362.3 117.6%  
Dividends per share (Unadj.) Rs14.0011.00 127.3%  
Dividend yield (eoy) %0.91.3 72.5%  
Book value per share (Unadj.) Rs257.1388.8 66.1%  
Shares outstanding (eoy) m169.2216.60 1,019.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.31.3 320.7%   
Avg P/E ratio x26.818.4 145.4%  
P/CF ratio (eoy) x20.113.5 149.2%  
Price / Book Value ratio x5.72.2 265.4%  
Dividend payout %25.424.1 105.5%   
Avg Mkt Cap Rs m249,88713,969 1,788.9%   
No. of employees `00011.81.6 744.2%   
Total wages/salary Rs m9,9341,487 668.2%   
Avg. sales/employee Rs Th4,971.56,631.9 75.0%   
Avg. wages/employee Rs Th843.2939.2 89.8%   
Avg. net profit/employee Rs Th792.4479.4 165.3%   
INCOME DATA
Net Sales Rs m58,56910,498 557.9%  
Other income Rs m2,233242 921.2%   
Total revenues Rs m60,80210,741 566.1%   
Gross profit Rs m13,7731,135 1,213.1%  
Depreciation Rs m3,069276 1,114.0%   
Interest Rs m2,0560-   
Profit before tax Rs m10,8811,102 987.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,545343 450.1%   
Profit after tax Rs m9,336759 1,230.2%  
Gross profit margin %23.510.8 217.4%  
Effective tax rate %14.231.1 45.6%   
Net profit margin %15.97.2 220.5%  
BALANCE SHEET DATA
Current assets Rs m53,8416,410 840.0%   
Current liabilities Rs m31,6128,828 358.1%   
Net working cap to sales %38.0-23.0 -164.7%  
Current ratio x1.70.7 234.6%  
Inventory Days Days9758 168.5%  
Debtors Days Days8438 218.2%  
Net fixed assets Rs m42,0791,406 2,992.0%   
Share capital Rs m846166 509.8%   
"Free" reserves Rs m42,6556,286 678.6%   
Net worth Rs m43,5016,455 674.0%   
Long term debt Rs m22,4080-   
Total assets Rs m101,2508,828 1,146.9%  
Interest coverage x6.3NM-  
Debt to equity ratio x0.50-  
Sales to assets ratio x0.61.2 48.6%   
Return on assets %11.38.6 130.9%  
Return on equity %21.511.8 182.5%  
Return on capital %19.617.1 114.9%  
Exports to sales %08.3 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA869 0.0%   
Imports (cif) Rs mNA2,209 0.0%   
Fx inflow Rs m20,066959 2,092.9%   
Fx outflow Rs m5,3042,612 203.1%   
Net fx Rs m14,762-1,653 -893.0%   
CASH FLOW
From Operations Rs m10,1271,070 946.1%  
From Investments Rs m-7,869-750 1,049.6%  
From Financial Activity Rs m-1,918-150 1,280.4%  
Net Cashflow Rs m212171 123.8%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 7.0 18.2 38.6%  
FIIs % 12.6 1.0 1,260.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 29.1 30.2%  
Shareholders   26,511 28,591 92.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   TTK HEALTHCARE  ALEMBIC LTD  CIPLA  ELDER PHARMA  SUVEN LIFE  

Compare TORRENT PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Feb 19, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - ALEMBIC LTD COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS